Alpha Tau Medical is on its way to transform cancer treatment in Japan with its groundbreaking Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) — a revolutionary approach that delivers highly localized alpha radiation directly into tumors while sparing healthy tissue.

With $83M in liquidity, multiple FDA IDEs cleared in the U.S., and a pivotal head and neck cancer trial completed in Japan, Alpha Tau now stands on the threshold of potential PMDA approval.

Backed by strong clinical results and visionary leadership, Alpha Tau is poised for rapid market expansion and long-term impact in Japan’s oncology landscape.

Join us on November 11th in Tokyo for an exclusive in-person event with Chairman Uzi Sofer, CFO Raphi Levy, and HekaBio K.K. CEO Rob Claar as they share the company’s journey, insights, and future plans.

👉 RSVP now to secure your seat and be part of the conversation shaping the next frontier of cancer therapy.
https://luma.com/vzd0ysp2